Alphaknife for glioma tumors: two years experiences with targeted alpha therapy of 213Bi-substance P
Glioblastoma multiforme (GBM) is characterized by the worst prognosis with an overall survival (OS) 9-15 months, median 13 months. The infiltrating character of the tumor, molecular heterogeneity, as well as the protective effects of blood-brain barrier are the causes of insufficient front line treatments (surgery, radio and chemotherapy); 90% of patients have a recurrence at the original tumor location. Therefore a new type of strategies must be implemented and proofed.
It has been demonstrated that NK-1 receptor system is extensively expressed in glioma cells, and substance P can be used as a ligand for targeted therapy. On the other hand alpha emitter, like 213Bi offers the new potential for selective irradiation of tumors, with minimizing damage to adjacent tissue.
KROLICKI Leszek;
MORGENSTERN Alfred;
KUNIKOWSKA Jolanta;
KOZIARA H;
KROLICKI B;
JAKUCINSKI M;
APOSTOLIDIS Christos;
BRUCHERTSEIFER Frank;
2014-12-12
SPRINGER
JRC91273
1619-7070,
https://publications.jrc.ec.europa.eu/repository/handle/JRC91273,
10.1007/s00259-014-2901-9,
Additional supporting files
| File name | Description | File type | |
|---|
